S&P 500
7,666.60
+35.13
+0.46%
Dow
53,061.95
+295.05
+0.56%
Nasdaq
26,217.83
+118.06
+0.45%
NYSE Composite
24,495.55
+146.25
+0.60%
Russell 2000
2,953.17
+33.04
+1.13%
VIX
15.36
+0.16
+1.05%
LLY · Eli Lilly & Co.
NEW YORK STOCK EXCHANGE, INC. - Real Time Price • USD
Eli Lilly and Co (LLY)
NEW YORK STOCK EXCHANGE, INC.
Pharmaceuticals
$1159.72
-0.03
(-0.00%)
● At close: September 2 at 4:00:00 PM EDT
$1168.46
+8.40
(+0.72%)
Pre-Market:
8:20:27 AM EDT
DAY'S RANGE
$1159.72
$1158.87
$1187.19
52-WEEK RANGE
$1159.72
$712.05
$1292.65
What's happening
- LLY is down 0.00% today, trading at $1159.72. — Live quote
- Volume today (109,861) is well below its 3-month average of 3,038,770. (Finnhub fundamentals)
- Last quarter's EPS beat estimates: $8.38 actual vs. $6.07 estimated (+38.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 11
Buy 19
Hold 7
Sell 1
Strong sell 0
Aggregate ratings for 2026-09-01 (38 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
LLY
+7.95%
vs S&P 500
-4.26%
1-YEAR RETURN
LLY
+57.23%
vs S&P 500
+38.37%
6-MONTH RETURN
LLY
+10.27%
3-MONTH RETURN
LLY
+9.01%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-08-05 (Q2 2026)
$8.38
Est. $6.07
BEAT +38.1%
2026-04-26 (Q1 2026)
$8.55
Est. $6.73
BEAT +27.0%
2026-01-26 (Q4 2025)
$7.54
Est. $6.74
BEAT +11.9%
2025-10-26 (Q3 2025)
$7.02
Est. $5.75
BEAT +22.0%
Valuation Measures & Ratios
Enterprise Value4$1,199.12B
Forward P/E528.48
PEG Ratio61.48
Price / Sales (TTM1)14.47
Price / Book733.34
EV4 / Revenue15.05
EV4 / EBITDA33.56
Profit Margin33.53%
Operating Margin42.22%
Return on Equity (ROE8)92.58%
Return on Assets (ROA9)21.97%
Avg Volume (3M)3,038,770
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1,070.20B | $820.94B | $681.51B | $695.44B | $736.51B |
| P/E | 41.59 | 38.36 | 45.52 | 56.28 | 82.39 |
| Price/Sales | 14.09 | 12.50 | 11.89 | 13.63 | 16.65 |
| Price/Book | 31.59 | 26.31 | 28.64 | 38.06 | 46.72 |
| EV/Revenue | 14.61 | 13.02 | 12.43 | 14.23 | 17.36 |
| ROE | 75.96% | 68.59% | 62.93% | 67.63% | 56.70% |
| ROA | 18.09% | 18.36% | 13.03% | 12.24% | 10.00% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short6,564,742
Change from Prior Settlement-28.00%
% of Float—
Days to Cover (Short Ratio)2.11
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Loading chart…
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 47.7% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 33.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is +57.2%. Finnhub market metrics ↗
Potential concerns
- Trailing P/E is 43.2, a high price relative to reported earnings. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-08-18; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on LLY
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.97B | $19.80B | $17.60B | $15.56B | $12.73B | $11.44B | $11.30B | $8.77B |
| Net income | $7.09B | $7.40B | $5.58B | $5.66B | $2.76B | $970.3M | $2.97B | $2.24B |
| EPS (diluted) | $7.94 | $8.26 | $6.21 | $6.29 | $3.06 | $1.07 | $3.28 | $2.48 |
| EPS (basic) | $7.95 | $8.27 | $6.22 | $6.30 | $3.07 | $1.08 | $3.29 | $2.49 |
| Net margin | $31 | $37 | $32 | $36 | $22 | $8 | $26 | $26 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $142.28B | $116.58B | $112.48B | $114.94B | $100.92B | $89.39B | $78.72B | $75.61B |
| Stockholders' equity | $33.88B | $31.20B | $26.54B | $23.79B | $18.27B | $15.76B | $14.27B | $14.24B |
| Total current assets | $64.67B | $54.84B | $55.63B | $62.07B | $49.85B | $41.26B | $32.74B | $31.42B |
| Total current liabilities | $47.74B | $36.63B | $35.23B | $40.14B | $39.02B | $30.07B | $28.38B | $24.67B |
| Cash & equivalents | $8.95B | $5.28B | $7.27B | $9.79B | $3.38B | $3.09B | $3.27B | $3.37B |
| Marketable securities (current) | — | — | — | $121.6M | $170.1M | $127.4M | $154.8M | $149.4M |
| Accounts receivable | $20.08B | $18.43B | $17.76B | $16.11B | $14.17B | $12.04B | $11.01B | $10.29B |
| Inventory | $16.79B | $14.53B | $13.74B | $12.18B | $11.01B | $9.31B | $7.59B | $7.46B |
| Other current assets | $86.0M | $214.0M | $147.0M | $271.5M | $68.8M | $72.4M | $266.0M | $134.6M |
| Marketable securities (non-current) | $3.86B | $3.12B | $2.80B | $2.81B | $3.21B | $3.22B | $3.22B | $3.20B |
| Property, plant & equipment | $29.29B | $26.54B | $24.68B | $22.32B | $20.53B | $18.47B | $17.10B | $16.17B |
| Goodwill | $8.85B | $6.13B | $5.90B | $5.90B | $5.77B | $5.77B | $5.77B | $5.77B |
| Intangible assets | $18.11B | $7.37B | $6.52B | $6.45B | $5.91B | $6.01B | $6.17B | $6.54B |
| Other non-current assets | $7.48B | $7.23B | $6.99B | $6.43B | $6.23B | $6.07B | $5.72B | $5.12B |
| Accounts payable | $6.11B | $5.03B | $5.38B | $4.26B | $4.08B | $3.44B | $3.23B | $2.89B |
| Short-term debt | — | — | $0 | — | — | — | $4.34B | — |
| Other current liabilities | $11.66B | $8.70B | $8.46B | $5.22B | $5.08B | $3.77B | $6.40B | $5.58B |
| Long-term debt | $47.86B | $39.37B | $40.87B | $40.87B | $34.18B | $34.50B | $28.53B | $29.05B |
| Other non-current liabilities | $7.34B | $4.08B | $3.97B | $3.78B | $2.34B | $2.29B | $3.48B | $2.24B |
| Common stock & paid-in capital | $588.0M | $590.0M | $590.0M | $591.4M | $592.0M | $592.6M | $592.0M | $593.9M |
| Retained earnings | $31.89B | $29.51B | $24.47B | $22.25B | $17.38B | $15.10B | $13.54B | $13.63B |
| Accumulated other comprehensive income (loss) | -$2.76B | -$2.83B | -$2.88B | -$3.21B | -$3.72B | -$3.77B | -$4.32B | -$4.27B |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.69B | $5.33B | $3.22B | $8.84B | $3.09B | $1.67B | $2.47B | $3.71B |
| Investing cash flow | -$15.40B | -$3.92B | -$2.80B | -$2.98B | -$1.83B | -$3.35B | -$1.92B | -$4.00B |
| Financing cash flow | $8.43B | -$3.47B | -$2.88B | $530.8M | -$1.25B | $1.38B | -$225.5M | $211.3M |
| Depreciation & amortization | $534.0M | $509.0M | $585.7M | $470.3M | $478.0M | $463.0M | $485.2M | $466.8M |
| Share-based compensation | $201.0M | $161.0M | $136.1M | $150.9M | $185.0M | $154.0M | $142.3M | $133.2M |
| Deferred income taxes | — | — | -$1.71B | — | — | — | -$2.68B | — |
| Change in inventory | — | — | $4.67B | — | — | — | $2.51B | — |
| Other investing activities | $127.0M | $31.0M | -$56.8M | $307.8M | -$141.0M | -$111.0M | $678.2M | -$373.2M |
| Dividends paid | $1.55B | $1.55B | $1.35B | $1.35B | $1.35B | $1.35B | $1.17B | $1.17B |
| Share repurchases | $1.60B | $2.36B | $1.51B | $708.3M | $692.0M | $1.20B | $2.05B | $446.1M |
| Debt issued | $8.94B | $0 | -$200.0K | $6.71B | $0 | $6.46B | -$100.0K | $4.96B |
| Debt repaid | $873.0M | $750.0M | -$100.0K | $100.0K | $778.0M | $0 | -$200.0K | $0 |
| Other financing activities | -$4.0M | -$591.0M | -$25.1M | -$29.9M | -$31.0M | -$686.0M | -$45.9M | -$47.3M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B |
| EPS (diluted) | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
| EPS (basic) | $23.00 | $11.76 | $5.82 | $6.93 | $6.15 |
| Net margin | $32 | $24 | $15 | $22 | $20 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B |
| Stockholders' equity | $26.54B | $14.27B | $10.77B | $10.65B | $8.98B |
| Total current assets | $55.63B | $32.74B | $25.73B | $18.03B | $18.45B |
| Total current liabilities | $35.23B | $28.38B | $27.29B | $17.14B | $15.05B |
| Cash & equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B |
| Marketable securities (current) | — | $154.8M | $109.1M | $144.8M | $90.1M |
| Accounts receivable | $17.76B | $11.01B | $9.09B | $6.90B | $6.67B |
| Inventory | $13.74B | $7.59B | $5.77B | $4.31B | $3.89B |
| Other current assets | $147.0M | $266.0M | $149.5M | $7.3M | — |
| Marketable securities (non-current) | $2.80B | $3.22B | $3.05B | $2.90B | $3.21B |
| Property, plant & equipment | $24.68B | $17.10B | $12.91B | $10.14B | $8.99B |
| Goodwill | $5.90B | $5.77B | $4.94B | $4.07B | $3.89B |
| Intangible assets | $6.52B | $6.17B | $6.91B | $7.21B | $7.69B |
| Other non-current assets | $6.99B | $5.72B | $4.99B | $4.34B | — |
| Accounts payable | $5.38B | $3.23B | $2.60B | $1.93B | $1.67B |
| Short-term debt | $0 | $4.34B | $6.19B | $1.50B | $0 |
| Other current liabilities | $8.46B | $6.40B | $3.28B | $2.85B | $3.03B |
| Long-term debt | $40.87B | $28.53B | $18.32B | $14.74B | $15.35B |
| Other non-current liabilities | $3.97B | $3.48B | $2.24B | $1.82B | $1.64B |
| Common stock & paid-in capital | $590.0M | $592.0M | $593.6M | $594.1M | $596.3M |
| Retained earnings | $24.47B | $13.54B | $10.31B | $10.04B | $8.96B |
| Accumulated other comprehensive income (loss) | -$2.88B | -$4.32B | -$4.33B | -$3.84B | -$4.34B |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B |
| Investing cash flow | -$10.97B | -$9.30B | -$7.15B | -$3.76B | -$2.87B |
| Financing cash flow | -$2.21B | $1.23B | $3.50B | -$5.41B | -$4.13B |
| Depreciation & amortization | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B |
| Share-based compensation | $626.0M | $646.0M | $629.0M | $371.1M | $342.8M |
| Deferred income taxes | -$1.71B | -$2.68B | -$2.34B | -$2.19B | -$802.3M |
| Change in inventory | $4.67B | $2.51B | $1.43B | $599.7M | $235.9M |
| Other investing activities | -$1.0M | $248.0M | $98.0M | $302.2M | $191.7M |
| Dividends paid | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B |
| Share repurchases | $4.11B | $2.50B | $750.0M | $1.50B | $1.25B |
| Debt issued | $13.17B | $11.42B | $3.96B | $0 | $2.41B |
| Debt repaid | $778.0M | $664.0M | $0 | $1.56B | $1.91B |
| Other financing activities | -$772.0M | -$491.0M | -$335.0M | -$308.9M | -$295.9M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding LLY as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers64.8%
Shares Outstanding892,400,000
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | 90,376,978 | $108.40B | 10.13% | -1.7% | 2026-07-23 |
| BlackRock, Inc. | 67,540,400 | $81.01B | 7.57% | +1.7% | 2026-08-07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 53,528,868 | $64.20B | 6.00% | +0.3% | 2026-06-30 |
| Pnc Financial Services Group, Inc. | 51,120,779 | $61.32B | 5.73% | -0.0% | 2026-08-07 |
| State Street Corp | 36,215,754 | $43.44B | 4.06% | +1.7% | 2026-08-07 |
| FMR LLC | 28,462,475 | $34.14B | 3.19% | +8.1% | 2026-08-13 |
| Capital Research Global Investors | 20,873,140 | $25.04B | 2.34% | -15.3% | 2026-08-07 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 20,859,217 | $25.02B | 2.34% | -0.6% | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 20,310,858 | $24.28B | 2.28% | +0.6% | 2026-08-12 |
| Morgan Stanley | 16,226,398 | $19.46B | 1.82% | +5.1% | 2026-08-11 |
| Capital World Investors | 15,902,642 | $19.08B | 1.78% | +1.8% | 2026-08-07 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 13,911,839 | $16.7M | 1.56% | -0.6% | 2026-08-14 |
| Jpmorgan Chase & Co | 12,598,524 | $15.50B | 1.41% | -8.0% | 2026-08-12 |
| NORGES BANK | 11,471,413 | $13.76B | 1.29% | +0.0% | 2026-08-12 |
| Bank Of America Corp /De/ | 11,274,243 | $13.52B | 1.26% | +1.3% | 2026-08-14 |
| WELLINGTON MANAGEMENT GROUP LLP | 10,998,953 | $13.19B | 1.23% | -18.1% | 2026-08-14 |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 10,759,188 | $12.90B | 1.21% | +0.0% | 2026-07-28 |
| PRIMECAP MANAGEMENT CO/CA/ | 9,172,904 | $11.00B | 1.03% | -0.5% | 2026-08-14 |
| Northern Trust Corp | 8,796,866 | $10.55B | 0.99% | -0.3% | 2026-08-12 |
| Goldman Sachs Group Inc | 7,652,960 | $9.18B | 0.86% | +20.7% | 2026-08-14 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 7,209,385 | $8.65B | 0.81% | +1.9% | 2026-08-13 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 6,001,955 | $7.20B | 0.67% | +1.8% | 2026-08-14 |
| Sixth Street Partners Management Company, L.P. | 6,001,955 | $7.20B | 0.67% | +0.0% | 2026-08-13 |
| Capital International Investors | 5,734,768 | $6.88B | 0.64% | -6.2% | 2026-08-07 |
| JENNISON ASSOCIATES LLC | 5,461,416 | $6.55B | 0.61% | +7.9% | 2026-08-03 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-20 to 2026-08-17
Recent transactions
- Insiders have net sold 31,828 shares over the last 182 days, across 0 purchases and 6 sales.
- Most recent: Sulzberger Gabrielle (Director) — Grant / award of 4 shares on 2026-08-17.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)31,828 sh(6 txns)
Net Shares-31,828
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Sulzberger Gabrielle | Director | Grant / award | 2026-08-17 | 4 |
| LUCIANO JUAN R | Director | Grant / award | 2026-08-17 | 13 |
| Fyrwald J Erik | Director | Grant / award | 2026-08-17 | 8 |
| Alvarez Ralph | Director | Grant / award | 2026-08-17 | 10 |
| Jonsson Patrik | EVP & President, LLY Int'l | Open market sale | 2026-08-17 | 6,500 |
| Zakrowski Donald A | SVP, Finance, & CAO | Open market sale | 2026-08-10 | 2,000 |
| Hakim Anat | EVP, GC & Secretary | Open market sale | 2026-08-07 | 5,000 |
| Seymour Melissa | EVP, Global Quality | Option exercise | 2026-08-01 | 981 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | Open market sale | 2026-06-10 | 2,500 |
| LILLY ENDOWMENT INC | Reporting person | Open market sale | 2026-05-06 | 13,620 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-17 | Sulzberger Gabrielle | Director | Grant / award | 4 | $1183.16 |
| 2026-08-17 | LUCIANO JUAN R | Director | Grant / award | 13 | $1183.16 |
| 2026-08-17 | Fyrwald J Erik | Director | Grant / award | 8 | $1183.16 |
| 2026-08-17 | Alvarez Ralph | Director | Grant / award | 10 | $1183.16 |
| 2026-08-17 | Jonsson Patrik | EVP & President, LLY Int'l | Open market sale | 6,500 | $1175.10 |
| 2026-08-10 | Zakrowski Donald A | SVP, Finance, & CAO | Open market sale | 2,000 | $1185.01 |
| 2026-08-07 | Hakim Anat | EVP, GC & Secretary | Open market sale | 5,000 | $1190.00 |
| 2026-08-01 | Seymour Melissa | EVP, Global Quality | Option exercise | 981 | $0.00 |
| 2026-08-01 | Seymour Melissa | EVP, Global Quality | Tax withholding | 439 | $1148.84 |
| 2026-07-20 | Sulzberger Gabrielle | Director | Grant / award | 4 | $1146.90 |
| 2026-07-20 | LUCIANO JUAN R | Director | Grant / award | 14 | $1146.90 |
| 2026-07-20 | Fyrwald J Erik | Director | Grant / award | 9 | $1146.90 |
| 2026-07-20 | Alvarez Ralph | Director | Grant / award | 11 | $1146.90 |
| 2026-06-15 | Sulzberger Gabrielle | Director | Grant / award | 4 | $1129.35 |
| 2026-06-15 | LUCIANO JUAN R | Director | Grant / award | 14 | $1129.35 |
| 2026-06-15 | Fyrwald J Erik | Director | Grant / award | 9 | $1129.35 |
| 2026-06-15 | Alvarez Ralph | Director | Grant / award | 11 | $1129.35 |
| 2026-06-10 | Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | Open market sale | 2,500 | $1150.77 |
| 2026-05-18 | Sulzberger Gabrielle | Director | Grant / award | 5 | $988.09 |
| 2026-05-18 | LUCIANO JUAN R | Director | Grant / award | 16 | $988.09 |
| 2026-05-18 | Fyrwald J Erik | Director | Grant / award | 10 | $988.09 |
| 2026-05-18 | Alvarez Ralph | Director | Grant / award | 13 | $988.09 |
| 2026-05-06 | LILLY ENDOWMENT INC | Reporting person | Open market sale | 13,620 | $995.23 |
| 2026-05-06 | LILLY ENDOWMENT INC | Reporting person | Open market sale | 2,208 | $996.18 |
| 2026-04-20 | Sulzberger Gabrielle | Director | Grant / award | 5 | $919.90 |
| 2026-04-20 | LUCIANO JUAN R | Director | Grant / award | 17 | $919.90 |
| 2026-04-20 | Fyrwald J Erik | Director | Grant / award | 11 | $919.90 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 12:21 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-08-03 | 4 | 2026-08-01 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-20 | View on SEC.gov → |
Recent news
Headlines about LLY (Eli Lilly & Co.). Links open the publisher — we don’t host full articles.
-
Superluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the Clinic
Yahoo · 2026-09-03 -
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
Yahoo · 2026-09-03 -
Mounjaro Vs Trulicity: Eli Lilly’s New FDA Win Puts Its Blockbuster Weight-Loss Drug In Focus
Stocktwits · 2026-09-02 -
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
Yahoo · 2026-09-02 -
Eli Lilly Just Announced a Major Acquisition. Here's What It Means.
Yahoo · 2026-09-02 -
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
Yahoo · 2026-09-02 -
How Did Merck Stock Beat The Market With Slowing Sales?
Yahoo · 2026-09-02 -
Lilly’s Record Stock Price Is Hiding an Even Bigger Opportunity
Yahoo · 2026-09-02
No headlines in this category right now — try “All”.